JAMA psychiatry

Childhood and Teen ADHD Linked to Higher Risk of Later Psychotic Disorders

Updated

Abstract

A diagnosis of ADHD in childhood is associated with a 4.74-fold increase in the risk of subsequent psychotic disorder.

  • This analysis included 15 studies with a total of 1.85 million participants.
  • The pooled relative effect indicates a significant association between childhood ADHD and the development of psychotic disorders.
  • Subgroup analyses revealed consistent risk estimates for various types of psychotic disorders, including schizophrenia.
  • No significant differences were found based on study design or whether the risk estimates were adjusted or unadjusted.
  • Meta-regressions showed no significant effects when considering sex and bias as covariates.
  • The findings underscore the need for further research to explore the mechanisms linking ADHD and psychotic disorders.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflict of Interest Disclosures: Dr Nourredine reported receiving nonfinancial support from HAC Pharma and Janssen-Cilag Ltd outside the submitted work. Dr Rolland reported receiving personal fees from Shire plc and nonfinancial support from HAC Pharma during the conduct of the study and personal fees from Indivior plc, Ethypharm, Grünenthal, Jansen Global Services, LLC, Otsuka Pharmaceutical Co, Ltd, Gilead Sciences, Inc, and AbbVie, grants from Camurus AB, Gilead Sciences, Inc, and Merck Sharp & Dohme, and nonfinancial support from Recordati SpA outside the submitted work. Dr Falissard reported receiving personal fees from Eli Lilly and Company, Bristol Myers Squibb, Servier Laboratories, GlaxoSmithKline, HRA Pharma, F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Almirall, SA, Allergan Plc, Stallergenes Greer, Sanofi Genzyme, Pierre Fabre Group, AstraZeneca, Novartis AG, Janssen Global Services, LLC, Astellas Pharma US, Inc, Biotronik, Daiichi Sankyo Company Limited, Gilead Sciences, Inc, Merck Sharp & Dohme, H Lundbeck A/S, Actelion Pharmaceuticals US, Inc, AbbVie, Alnylam Pharmaceuticals, Inc, Amgen, Inc, Biocodex, Biogen, BioSpec, Bioprojet, Biotronik, Celgène Corporation, Chiesi USA, Inc, D&A Pharma, Eisai Co, Ltd, Ethypharm, Laboratoires Genevrier, Grünenthal, IDM Pharma Inc, Idorsia Pharmaceuticals Ltd, Indivior PLC, LÉO Pharma A/S, The Menarini Group, Novo Nordisk A/S, Otsuka Pharmaceutical Co, Ltd, Pfizer, Inc, Recordati SpA, Takeda Pharmaceutical Company Limited, and UCB SA outside the submitted work. Dr Jurek reported receiving personal fees from Servier Laboratories outside the submitted work. No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free